Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21877851 | 0.88 | MAPT (0.50) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL1665801 | 0.86 | MAPT (0.46) | MAPTLMNAALDH1A1TSHRCA12 | |
| SCHEMBL11546922 | 0.82 | MAPT (0.76) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL11550827 | 0.82 | MAPT (0.82) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL2653971 | 0.82 | ATM (0.49) | MAPTLMNAALDH1A1TDP1CA12 | |
| SCHEMBL20982585 | 0.81 | MAPT (0.61) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL20982587 | 0.81 | MAPT (0.61) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL20982502 | 0.81 | MAPT (0.61) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL11549910 | 0.81 | MAPT (0.79) | MAPTLMNAALDH1A1TSHRTDP1 | |
| SCHEMBL11546818 | 0.81 | MAPT (0.79) | MAPTLMNAALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450354-B2 | Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2549874-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8350039-B2 | Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101125-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2424533-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2424866-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2011119465-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237570-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2010126743-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126745-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237570-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | MAPT 9/4885LMNA 871/4885ALDH1A1 2437/4885 |
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | MAPT 10/4885LMNA 1130/4885ALDH1A1 2155/4885 |
| US-20120101125-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | MAPT 7/4885LMNA 785/4885ALDH1A1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.